Thrombin Generation During Cardiopulmonary Bypass With Titrated Versus Conventional Anticoagulation Management.

NCT ID: NCT03347201

Last Updated: 2020-12-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-10-02
• Study Completion Date: 2019-05-28

Brief Summary

In this study, the investigators will be comparing anticoagulation for Cardiopulmonary Bypass (CPB) guided by the Hemostasis Management System (HMS Plus) with the current dosing based on weight and ACT measurements.

The primary objective of this study is to determine whether relative to patients with conventional management, those managed with the HMS Plus have improved thrombin generation after CPB.

The secondary objective is to determine if patients in the HMS Plus group have reduced blood loss in the first 24 hours following surgery compared with patients in the conventional group.

Detailed Description

Cardiopulmonary bypass (CPB) allows cardiac surgery to be performed on a motionless, bloodless heart while maintaining circulation to the rest of the body. Anticoagulation with heparin prevents the body's clotting system from being activated when blood comes into contact with the walls of the bypass circuit. The amount of heparin given to achieve this effect is determined on a weight-based dosing and monitored with a point-of-care monitor called ACT (activated clotting time). However, there remains a high level of variability in the concentration of heparin in the blood and the ACT is affected by hypothermia and dilution of the blood, both of which commonly occur during CPB for cardiac surgery.

The Hemostasis Management System (HMS Plus) offers an alternative way of dosing and monitoring heparin by aiming to achieve a pre-determined heparin concentration throughout CPB, rather than being determined by the ACT. It also aims to determine the dose of protamine, the drug used to reverse heparin at the end CPB, required based on residual heparin concentration rather than on a 1:1 ratio of the total dose of heparin given which is the common current practice. The benefits of using this system are proposed to be more effective anticoagulation during CPB meaning less of the body's reserves of clotting factors are consumed. This could mean potentially less bleeding and decrease requirement of blood products following surgery.

Conditions

Cardiac Surgery

Keywords

Cardiopulmonary bypass, Heparin, Protamine

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: SINGLE

Study Groups

Intervention Group

1. Initial heparin bolus before CPB to be calculated using HMS Plus.

2. Following commencement of CPB further heparin requirements will be determined using the HMS Plus. ACT's will also be checked whilst on CPB and if falls below 480 seconds, additional heparin will also be given.

3. Following cessation of CPB the dose of protamine required to reverse residual heparin will be calculated using the HMS Plus.

Group Type: EXPERIMENTAL

HMS Plus

Intervention Type: DEVICE

Subjects randomized to the intervention group will have their dose of Heparin and Protamine calculated by the HMS Plus.

Control Group

Patients in the control arm will undergo routine heparin anticoagulation using a weight based initial dose of 400 units/kg, aiming for an ACT of \>480 seconds. Further heparin doses (5000 to 10000 units) will be given if the ACT falls below 480 seconds whilst on bypass. At the end of CPB heparin will be reversed with protamine using 1:1 ratio based on the initial dose of heparin given pre-bypass. HMS Plus measures will also be conducted in this group for study purposes, but the results will not be made available to the clinicians.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

HMS Plus

Subjects randomized to the intervention group will have their dose of Heparin and Protamine calculated by the HMS Plus.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Scheduled to undergo non-emergent coronary artery bypass grafting, valve repair or replacement (with or without ascending aortic replacement) or a combination of these procedures requiring the use of CPB

Exclusion Criteria

• Less than 18 years old
• Planned use of deep hypothermic circulatory arrest
• Cases where use of brief circulatory arrest anticipated
• Highly complex cases (LVAD, Heart Transplant, Complex congenital)
• Significant liver dysfunction (liver enzymes > 2-fold higher than upper limit of normal
• Pre-existing coagulopathy (INR >1.5, PTT >45 seconds, fibrinogen < 1.0g/L, platelet count <100x109/L)
• Use of long acting oral anticoagulants
• Patients on heparin infusions pre-operatively
• Major hemoglobinopathies, thalassemia or iron storage diseases
• Previous diagnosis of HIT
• Lack of informed consent

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Health Network, Toronto

OTHER

Sponsor Role: lead

Responsible Party

Jo Carroll

Manager Anesthesia Research

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Keyvan Karkouti, MD

Role: PRINCIPAL_INVESTIGATOR

University Health Network, Toronto

Locations

Toronto General Hospital, University Health Network

Toronto, Ontario, Canada

Countries

Canada

References

Li H, Bartoszko J, Serrick C, Rao V, Karkouti K. Titrated versus conventional anticoagulation management for thrombin generation in cardiac surgery: a randomized controlled trial. Can J Anaesth. 2022 Sep;69(9):1117-1128. doi: 10.1007/s12630-022-02278-1. Epub 2022 Jul 8.

Reference Type: DERIVED

PMID: 35799088 (View on PubMed)

Other Identifiers

15-9761

Identifier Type: -

Identifier Source: org_study_id